Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

August 24, 2025 | John Murphy | Leave a Comment

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

Lucy Kerr • Flavio A. Cadegiani • Fernando Baldi • et. al.,, DOI: 10.7759/cureus.21272 This article has been corrected. See Kerr L, Cadegiani F A, Baldi F, et al. (March 24, 2022) Correction: Ivermectin Prophylaxis Used for COVID-19:…[...]

August 5, 2025 | John Murphy | Leave a Comment

COVID is still around and a risk to vulnerable people. What are the symptoms in 2025? And how long does it last?

by Meru Sheel, The Conversation Five years ago, COVID was all we could think about. Today, we'd rather forget about lockdowns, testing lines and social distancing. But the virus that sparked…[...]

July 30, 2025 | John Murphy | Leave a Comment

Low Vitamin D Increases Risk for Severe COVID

Low vitamin D levels might increase a person’s odds of a severe bout with COVID-19, a new study says. People with a vitamin D deficiency are 36% more likely to require…[...]

July 13, 2025 | John Murphy | Leave a Comment

Anxiety and Depression-Related Factors in Hospitalized Patients Diagnosed With Coronavirus Disease 2019: A Detailed Cross-Sectional Analysis From a Tertiary Center

Arzu Kaplanoglu • Arzu Sonmez • Oznur Yildirim • et. al.,DOI: 10.7759/cureus.77865 Abstract Aim During pandemic periods, psychogenic assessment and precautions are critical for patients requiring hospitalization. This study investigates the factors influencing anxiety levels in patients…[...]

May 17, 2025 | John Murphy | Leave a Comment

Early Identification of Severe COVID-19 Cases and the Need for ICU Care Based on Clinical and Laboratory Risk Factors

Jawad Mahmood • Muhammad Izhar Ul Haque • Maria Gul • Aliya Ayub • Fawwad A. Ansari • Wiqas Ahmad DOI: 10.7759/cureus.80611 Abstract Background and objective Treatment in ICUs became extremely difficult due to the growing number of coronavirus disease 2019…[...]

March 26, 2025 | John Murphy | Leave a Comment

D-dimer as a Predictor of ICU Admission and Mortality in COVID-19 Patients: Insights From a Two-Year Retrospective Study

Abstract Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced pneumonitis results in a prothrombotic and hypercoagulable state. Prognostic indicators are crucial for identifying patients at risk of complications. D-dimer, a…[...]

January 4, 2025 | John Murphy | Leave a Comment

5 things we know and still don’t know about COVID, 5 years after it appeared

By LAURAN NEERGAARD, and MIKE STOBBE Five years ago, a cluster of people in Wuhan, China, fell sick with a virus never before seen in the world. The germ didn’t have a name,…[...]

September 28, 2024 | John Murphy | Leave a Comment

Three-year outcomes of post-acute sequelae of COVID-19

Miao Cai, , Yan Xie, Eric J. Topol & Ziyad Al-Aly Nature Medicine volume 30, pages1564–1573 (2024) Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) in many organ…[...]

November 15, 2023 | John Murphy | Leave a Comment

Ventilator-associated pneumonia in ICU patients with severe pneumonia and respiratory failure

Sarah Jackson Published June 15, 2023 - 10.1172/JCI172643 The Journal of Clinical Medicine The COVID-19 pandemic resulted in an unprecedented number of patients hospitalized in intensive care units (ICUs) because of…[...]

November 14, 2023 | John Murphy | Leave a Comment

COVID-19 Therapeutics for Nonhospitalized Patients

Rajesh T. Gandhi, MD1; Preeti N. Malani, MD, MSJ2,3; Carlos del Rio, MD4, JAMA. 2022;327(7):617-618. doi:10.1001/jama.2022.0335 Substantial progress has been made in therapeutics for nonhospitalized patients with COVID-19, but supply of and access to treatment remain limited. This Viewpoint…[...]